<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03238924</url>
  </required_header>
  <id_info>
    <org_study_id>36616</org_study_id>
    <nct_id>NCT03238924</nct_id>
  </id_info>
  <brief_title>Prolonged Exposure and Oxytocin</brief_title>
  <official_title>Augmenting Prolonged Exposure Therapy for PTSD With Intranasal Oxytocin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Posttraumatic stress disorder (PTSD) is a chronic, debilitating anxiety disorder that may
      develop after direct or indirect exposure to traumatic events. Prolonged Exposure (PE) is a
      cognitive-behavioral psychotherapy modality with a wealth of empirical support demonstrating
      its efficacy to treat PTSD in a variety of populations. The neuropeptide oxytocin is a
      promising new pharmacotherapeutic agent with prominent anxiolytic effects . Despite a strong
      biological and theoretical rationale for investigating the potential effectiveness of
      augmenting PE with intranasal oxytocin, no studies to date have done so. The current study
      aims to address this important gap in the literature by examining changes in PTSD symptoms
      following PE treatment combined with a) 40 IU of intranasal oxytocin or b) placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">December 31, 2016</completion_date>
  <primary_completion_date type="Actual">December 31, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PTSD Symptom Severity</measure>
    <time_frame>Change from Baseline to end of treatment (10 weeks)</time_frame>
    <description>Clinician-Administered PTSD Scale (CAPS-5). CAPS-5 scores range from 0-120. Items are summed to obtain a total score with higher scores reflective of greater symptom severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PTSD Symptom Severity</measure>
    <time_frame>Change from Baseline to end of treatment (10 weeks)</time_frame>
    <description>PTSD Checklist (PCL). The PCL is a self-report measure which uses a 5-point scale to assess the frequency and severity of PTSD symptoms. Item responses are summed to obtain a total score ranging from 17-85 with greater scores reflective of greater symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression Symptom Severity</measure>
    <time_frame>Change from Baseline to end of treatment (10 weeks)</time_frame>
    <description>Beck Depression Inventory-II. The BDI-II is a self-report measure where each item is rated on a 0-3 scale and summed to obtain a total score. Greater scores are reflective of greater symptom severity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>PTSD</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 IU intranasal oxytocin spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is matching saline nasal spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>40 IU oxytocin nasal spray, self-administered</description>
    <arm_group_label>Oxytocin</arm_group_label>
    <other_name>Pitocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Saline nasal spray, self-administered</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female; any race or ethnicity; age 18-75 years.

          2. Able to provide informed consent and function at an intellectual level sufficient to
             allow accurate completion of the assessment instruments.

          3. Participants must be able to comprehend English.

          4. Meet DSM-5 criteria for current PTSD (assessed via the Clinician Administered PTSD
             Scale; CAPS).

          5. A CAPS score of 50 or greater.

          6. Participants may also meet criteria for a mood disorder (except bipolar affective
             disorder, see Exclusion Criteria) or anxiety disorders (e.g., agoraphobia, social
             phobia, generalized anxiety disorder). The inclusion of participants with affective
             and anxiety disorders is essential because of the marked frequency of the co-existence
             of mood and other anxiety disorders among patients with PTSD.

          7. Participants taking psychotropic medications will be required to be maintained on a
             stable dose for at least eight weeks before study initiation. Initiation or change of
             psychotropic medications during the course of the trial may interfere with
             interpretation of results.

        Exclusion Criteria:

          1. Participants meeting DSM-5 criteria for a history of or current psychotic or bipolar
             affective disorders, or with current suicidal or homicidal ideation and intent. Those
             participants will be referred clinically.

          2. Participants who would present a serious suicide risk or who are likely to require
             hospitalization during the course of the study. Those participants will be referred
             clinically.

          3. Participants on maintenance anxiolytic, antidepressant, or mood stabilizing
             medications, which have been initiated during the past 8 weeks.

          4. Participants meeting DSM-5 criteria for a substance use disorder, except caffeine or
             nicotine, within the past 12 months.

          5. Pregnant women will be excluded from the proposed study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2017</study_first_submitted>
  <study_first_submitted_qc>July 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2017</study_first_posted>
  <results_first_submitted>January 29, 2018</results_first_submitted>
  <results_first_submitted_qc>April 26, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 25, 2018</results_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Julianne Flanagan</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>posttraumatic stress disorder</keyword>
  <keyword>oxytocin</keyword>
  <keyword>Prolonged Exposure</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oxytocin</title>
          <description>40 IU intranasal oxytocin spray
Oxytocin: 40 IU oxytocin nasal spray, self-administered</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo is matching saline nasal spray
Placebos: Saline nasal spray, self-administered</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oxytocin</title>
          <description>40 IU intranasal oxytocin spray
Oxytocin: 40 IU oxytocin nasal spray, self-administered</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo is matching saline nasal spray
Placebos: Saline nasal spray, self-administered</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.63" spread="14.58"/>
                    <measurement group_id="B2" value="45.78" spread="15.09"/>
                    <measurement group_id="B3" value="43.82" spread="14.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PTSD Symptom Severity</title>
        <description>Clinician-Administered PTSD Scale (CAPS-5). CAPS-5 scores range from 0-120. Items are summed to obtain a total score with higher scores reflective of greater symptom severity.</description>
        <time_frame>Change from Baseline to end of treatment (10 weeks)</time_frame>
        <population>Data belonging to participants who completed the trial were examined.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin</title>
            <description>40 IU intranasal oxytocin spray
Oxytocin: 40 IU oxytocin nasal spray, self-administered</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo is matching saline nasal spray
Placebos: Saline nasal spray, self-administered</description>
          </group>
        </group_list>
        <measure>
          <title>PTSD Symptom Severity</title>
          <description>Clinician-Administered PTSD Scale (CAPS-5). CAPS-5 scores range from 0-120. Items are summed to obtain a total score with higher scores reflective of greater symptom severity.</description>
          <population>Data belonging to participants who completed the trial were examined.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.00" spread="12.74"/>
                    <measurement group_id="O2" value="17.71" spread="9.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PTSD Symptom Severity</title>
        <description>PTSD Checklist (PCL). The PCL is a self-report measure which uses a 5-point scale to assess the frequency and severity of PTSD symptoms. Item responses are summed to obtain a total score ranging from 17-85 with greater scores reflective of greater symptom severity.</description>
        <time_frame>Change from Baseline to end of treatment (10 weeks)</time_frame>
        <population>Data belonging to participants who completed the trial were examined.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin</title>
            <description>40 IU intranasal oxytocin spray
Oxytocin: 40 IU oxytocin nasal spray, self-administered</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo is matching saline nasal spray
Placebos: Saline nasal spray, self-administered</description>
          </group>
        </group_list>
        <measure>
          <title>PTSD Symptom Severity</title>
          <description>PTSD Checklist (PCL). The PCL is a self-report measure which uses a 5-point scale to assess the frequency and severity of PTSD symptoms. Item responses are summed to obtain a total score ranging from 17-85 with greater scores reflective of greater symptom severity.</description>
          <population>Data belonging to participants who completed the trial were examined.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.50" spread="19.53"/>
                    <measurement group_id="O2" value="29.71" spread="26.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depression Symptom Severity</title>
        <description>Beck Depression Inventory-II. The BDI-II is a self-report measure where each item is rated on a 0-3 scale and summed to obtain a total score. Greater scores are reflective of greater symptom severity.</description>
        <time_frame>Change from Baseline to end of treatment (10 weeks)</time_frame>
        <population>Data belonging to participants who completed the trial were examined.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin</title>
            <description>40 IU intranasal oxytocin spray
Oxytocin: 40 IU oxytocin nasal spray, self-administered</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo is matching saline nasal spray
Placebos: Saline nasal spray, self-administered</description>
          </group>
        </group_list>
        <measure>
          <title>Depression Symptom Severity</title>
          <description>Beck Depression Inventory-II. The BDI-II is a self-report measure where each item is rated on a 0-3 scale and summed to obtain a total score. Greater scores are reflective of greater symptom severity.</description>
          <population>Data belonging to participants who completed the trial were examined.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.67" spread="11.24"/>
                    <measurement group_id="O2" value="17.14" spread="17.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years.</time_frame>
      <desc>All adverse events were recorded.</desc>
      <group_list>
        <group group_id="E1">
          <title>Oxytocin</title>
          <description>40 IU intranasal oxytocin spray
Oxytocin: 40 IU oxytocin nasal spray, self-administered</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo is matching saline nasal spray
Placebos: Saline nasal spray, self-administered</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Julianne Flanagan</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-5569</phone>
      <email>Hellmuth@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

